title: Obstetric and perinatal outcome of babies born from sperm selected by MACS from a randomized controlled trial.
abstract: OBJECTIVE
  The purpose of this study is to assess outcomes after magnetic-activated cell sorting (MACS) technology on obstetric and perinatal outcomes compared with those achieved after swim up from randomized controlled trial.
  
  
  METHODS
  This is a two-arm, unicentric, prospective, randomized, and triple-blinded trial and has a total of 237 infertile couples, between October 2010 and January 2013. A total of 65 and 66 newborns from MACS and control group, respectively, were described.
  
  
  RESULTS
  MACS had no clinically relevant adverse effects on obstetric and perinatal outcomes. No differences were found for obstetric problems including premature rupture of membranes 6.1% (CI95% 0-12.8) vs. 5.9% (CI95% 0-12.4), 1st trimester bleeding 28.6% (CI95% 15.9-41.2) vs. 23.5% (CI95% 11.9-35.1), invasive procedures as amniocentesis 2.0% (CI95% 0-5.9) vs. 3.9% (CI95% 0-9.2), diabetes 14.3% (CI95% 4.5-24.1) vs. 9.8% (CI95% 1.6-17.9), anemia 6.1% (CI95% 0-12.8) vs. 5.9%(CI95% 0-12.4), 2nd and 3rd trimesters 10.2% (CI95% 1.7-18.7) vs. 5.9% (CI95% 0-12.4), urinary tract infection 8.2% (CI95% 0.5-15.9) vs. 3.9% (CI95% 0-9.2), pregnancy-induced hypertension 6.1% (CI95% 0-12.8) vs. 15.7% (CI95% 5.7-25.7), birth weight (g) 2684.10 (CI95% 2499.48-2868.72) vs. 2676.12 (CI95% 2499.02-2852.21), neonatal height (cm) 48.3 (CI95% 47.1-49.4) vs. 46.5 (CI95% 44.6-48.4), and gestational cholestasis 0%(CI95% 0-0) vs. 3.9% (CI95% 0-9.2), respectively, in MACS group compared with control group.
  
  
  CONCLUSIONS
  Our data suggest that MACS technology does not increase or decrease Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation adverse obstetric and perinatal outcomes in children conceived when this technology was performed, being the largest randomized control trial with live birth reported results with MACS.
authors.affiliation: Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Romany
authors.affiliation: Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Garrido
authors.affiliation: Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Cobo
authors.affiliation: Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain.
authors.forename: Belen
authors.initials: B
authors.lastname: Aparicio-Ruiz
authors.affiliation: Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Serra
authors.affiliation: Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain. marcos.meseguer@ivi.es.|Instituto Valenciano de Infertilidad, Plaza de la Policía Local, 3, Valencia, 46015, Spain. marcos.meseguer@ivi.es.
authors.forename: Marcos
authors.initials: M
authors.lastname: Meseguer
mesh_terms: D000328:Adult; D001724:Birth Weight; D002469:Cell Separation / Q000379:methods; D002780:Cholestasis, Intrahepatic / Q000473:pathology; D005260:Female; D005307:Fertilization in Vitro; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000473:pathology; D007231:Infant, Newborn; D007246:Infertility / Q000473:pathology*; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000473:pathology*; D011256:Pregnancy Outcome; D047928:Premature Birth; D013094:Spermatozoa / Q000254:growth & development*
keywords: MACS technology; Obstetrics; Ovum donation program; Perinatal outcome; Sperm selection